Towards Healthcare Research & Consulting
HIV Drugs Market
Updated Date: 05 August 2026   |   Report Code: 5131
[email protected] +1 804-441-9344
Download Sample Order Now

HIV Drugs Market Growth, Innovations and Market Size Forecast 2035

According to forecasts, the global HIV drugs market size will grow from USD 34.75 billion in 2026 to USD 52.95 billion by 2035, with an expected CAGR of 4.3%. In 2025, combination-class drugs led the HIV drugs market with a 60% share, while hospital pharmacies dominated distribution at 50%. North America was the top region. Key players include ViiV Healthcare, Gilead, Janssen, Roche, Mylan, Theratechnologies, Boehringer Ingelheim, Cipla, Teva and Merck.

Last Updated : 05 August 2026 Category: Therapeutic Area Insight Code: 5131 Format: PDF / PPT / Excel

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global HIV Drugs Market Assessment

  • Overview
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America HIV Drugs Market Assessment

  • Overview
  • North America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • North America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Europe HIV Drugs Market Assessment

  • Overview
  • Europe HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Europe HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Asia Pacific HIV Drugs Market Assessment

  • Overview
  • Asia Pacific HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Asia Pacific HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Middle East and Africa HIV Drugs Market Assessment

  • Overview
  • Middle East and Africa HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Middle East and Africa HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

South America HIV Drugs Market Assessment

  • Overview
  • South America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • South America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Company Profiles

  • ViiV Healthcare
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan Pharmaceuticals Inc.
  • Theratechnologies Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Conclusion & Recommendations

FAQ's

Answer : HIV drugs market stands at USD 37.81 billion in 2026 and is expected to reach USD 55.23 billion by 2035, growing at a CAGR of 4.30% from 2026 to 2035.

Answer : North America, particularly the United States, leads the market for HIV drugs due to factors such as high healthcare spending, robust research and development infrastructure, and widespread access to treatment and care services.

Answer : World Health Organization, HHS.gov., Centers for Disease Control and Prevention, HIV.gov., National Institute of Health
Any Questions

Meet the Team

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar